Tertiary structure prediction and identification of druggable pocket in the cancer biomarker – Osteopontin-c by Subramaniam Sivakumar & Sivasitambaram Niranjali Devaraj
Sivakumar and Niranjali Devaraj Journal of Diabetes & Metabolic Disorders 2014, 13:13
http://www.jdmdonline.com/content/13/1/13RESEARCH ARTICLE Open AccessTertiary structure prediction and identification of
druggable pocket in the cancer biomarker –
Osteopontin-c
Subramaniam Sivakumar1,2* and Sivasitambaram Niranjali Devaraj2Abstract
Background: Osteopontin (Eta, secreted sialoprotein 1, opn) is secreted from different cell types including cancer
cells. Three splice variant forms namely osteopontin-a, osteopontin-b and osteopontin-c have been identified. The
main astonishing feature is that osteopontin-c is found to be elevated in almost all types of cancer cells. This was
the vital point to consider it for sequence analysis and structure predictions which provide ample chances for
prognostic, therapeutic and preventive cancer research.
Methods: Osteopontin-c gene sequence was determined from Breast Cancer sample and was translated to protein
sequence. It was then analyzed using various software and web tools for binding pockets, docking and druggability
analysis. Due to the lack of homological templates, tertiary structure was predicted using ab-initio method
server – I-TASSER and was evaluated after refinement using web tools. Refined structure was compared with known
bone sialoprotein electron microscopic structure and docked with CD44 for binding analysis and binding pockets
were identified for drug designing.
Results: Signal sequence of about sixteen amino acid residues was identified using signal sequence prediction
servers. Due to the absence of known structures of similar proteins, three dimensional structure of osteopontin-c
was predicted using I-TASSER server. The predicted structure was refined with the help of SUMMA server and was
validated using SAVES server. Molecular dynamic analysis was carried out using GROMACS software. The final model
was built and was used for docking with CD44. Druggable pockets were identified using pocket energies.
Conclusions: The tertiary structure of osteopontin-c was predicted successfully using the ab-initio method and the
predictions showed that osteopontin-c is of fibrous nature comparable to firbronectin. Docking studies showed the
significant similarities of QSAET motif in the interaction of CD44 and osteopontins between the normal and splice
variant forms of osteopontins and binding pockets analyses revealed several pockets which paved the way to the
identification of a druggable pocket.Background
Cancer results from alterations that disrupt the appropri-
ate controls and balances that direct normal cellular
growth and development. These changes resulting in
altered gene products or altered gene expression can
occur in two classes of genes that interact with each
other: genes that inhibit tumor suppressor genes and* Correspondence: sivabio@gmail.com
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distribution, and reproduction in any mediumgenes that facilitate cell growth and development [1].
Malignant tumors are characterized by dysregulated
growth control, the overcoming of replicative senescence
and the formation of metastases. Several growth factors
and cytokines play pivotal roles in the regulation of pro-
liferation, survival, adhesion and migration of neoplastic
cells [2]. Decades of scrutiny into the molecular basis of
cancer have largely focused on what causes oncogenic
transformation and the incipient emergence of tumors
[3]. The invasion of tumor cells is a complex, multistage
process. To facilitate the cell motility, invading cells need
to change the cell-cell adhesion properties, rearrange theee BioMed Central Ltd. This is an open access article distributed under the terms
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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recognize their cytoskeletons [4].
A biomarker is any substance, which when detected in
biological samples or tissue, is associated with an in-
creased risk of a disease. Serum biomarkers are produced
by body organs or tumors and when detected in high
amounts in the blood, can be suggestive of tumor activity.
These markers are nonspecific for cancer and can be pro-
duced by normal organs as well. Most biomarkers are
used infrequently for screening purposes. They are more
often used to evaluate treatment effects or to assess the
potential for metastatic disease in patients with established
disease. Osteopontin (OPN) was identified as one such
biomarker [5]. Osteopontin is a secreted glycoprotein that
plays important roles in a wide range of biological pro-
cesses, including tissue remodeling, inflammation, angio-
genesis, tumor development and immunity to infectious
disease [6]. Osteopontin also increases expression of
HIF-1α through phosphatidyl inositol 3′–kinase/Acutely
transforming retrovirus AKT8 in rodent T cell lymphoma
(PI3-K/Akt) pathway [7].
The OPN is a 32.5-kDa multifunctional protein with
multiple phosphorylation and glycosylation sites and con-
tains an arginine-glycine-aspartic acid-binding (RGD) do-
main as well as two heparin-binding sites, one thrombin
cleavage site (RSK [arginine-serine-lysine]) and a calcium-
binding site. The protein functions as both a cell attach-
ment protein and a cytokine that has a signaling function
through the action of two cell adhesion molecules: αvβ3-
integrin and CD44 [8]. It is also a tumor-associated pro-
tein, which mediates tumor transformation and malignant
progression. OPN has been proposed to promote tumor
progression through several mechanisms, including in-
creased cell survival, migration, invasion, neovasculariza-
tion, and modulation of immune function. The RGD
domain of OPN functionally mediates cell adhesion, mi-
gration and invasion through integrin engagement. Inter-
action between the RGD domain of OPN and integrin
receptors leads to Nuclear Factor-KappaB (NF-kB) and
Focal adhesion kinase (FAK) actvation mainly through
decreased apoptosis. These data indicate that the pre-
dominant mechanism, by which OPN promotes tumor
growth and metastasis through the RGD domain, is en-
hancement of survival in the tumor microenvironment
[9]. When OPN is cleaved at the RSK site by thrombin, it
is separated into two approximately equivalent sized
pieces, including N-terminal and C-terminal fragments.
Thrombin is activated by tissue factor (TF) which is over-
expressed on the surface of cancer cells. Both N-terminal
and C-terminal fragments increases adhesion and migra-
tion of cancer cells through interaction with integrins and
cyclophilin C respectively [10]. Enhanced OPN expression
has been detected at the tumor site as well as in plasma
and serum of patients with various types of cancers [11].The existence in humans, of two osteopontin splice vari-
ants with deletions of exon 4 referred to as osteopontin-c
or exon 5 called osteopontin-b and the normal osteopon-
tin referred as osteopontin-a has been described by Young
et al. [12]. Alternative splicing occurs in a region in a
molecule that is upstream of the central integrin binding
domain and the C-terminal CD44 binding domain. Inter-
estingly, osteopontin-b expressed by transfection is unstable
and the protein is degraded in the proteosome. In addition,
osteopontin-b RNA is present at consistently low levels of
expression in breast tissue specimens [13]. Osteopontin-a
was found to be expressed in both normal and cancer cells
to a lesser extent whereas osteopontin-c transcripts were
never detected in the normal tissue samples but were
present only in tumor cells [14]. The splice variant
osteopontin-c, which does not contain the sequence
encoded in exon-4, lacks an important domain for
calcium induced aggregation and transglutamination.
Lack of this domain forms the soluble form of the pro-
tein [15]. Among the three splice variants of osteopon-
tin expressed in breast cancer, the shortest form,
osteopontin-c, supports anchorage-independence more
effectively than the full length form, osteopontin-a.
Splice variant form, osteopontin-c, is brought about
through the gain of function by the cancer cells,
reflected in the activation of unique signal transduction
pathways. Osteopontin-c coordinately induces oxidore-
ductase genes that are associated with the mitochon-
drial energy metabolism and with the hexose mono
phosphate shunt [14].
Taken together, this growing list of studies suggests
that osteopontin blood levels have a potential as a prog-
nostic or diagnostic marker in prostate, breast, head and
neck and other cancers. It should be noted, however,
that osteopontin is unlikely to be a blood marker that is
specific to cancer because osteopontin levels are also ele-
vated in other conditions including sepsis, kidney disease
and cardiovascular disease. But, the identification of the
splice variant form of osteopontin-c solved this problem
[14]. In order to study further about the role and function
of osteopontin-c, the three dimensional structure
might be useful, which is yet to be determined through
x-ray crystallographic or NMR techniques. In this con-
text, in silico structure prediction of osteopontin-c




The web based tools were used for the purpose of trans-
lation, similarity studies, tertiary structure prediction,
model refinement, model evaluation, binding pockets
prediction and docking. The list of websites along with
web site addresses is shown in Table 1.
Table 1 Web based tool list








6. SAVES Server http://nihserver.mbi.ucla.edu/SAVES/
7. SUMMA http://silvio.cs.uno.edu/proteinrefinementserver/
8. PocketFinder http://www.modelling.leeds.ac.uk/pocketfinder/
9. Q-Site Finder http://www.modelling.leeds.ac.uk/qsitefinder/
10. ClusPro http://nrc.bu.edu/cluster/
11. DoGSiteScorer http://dogsite.zbh.uni-hamburg.de/
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Osteopontin-c gene sequence was determined from
breast cancer sample and it was translated to protein se-
quence using ExPASy Translate tool (http://web.expasy.
org/translate/) [16].
Sequence analysis
Signal sequence of osteopontin-c was predicted using sig-
nalP [17] and PrediSi servers [18,19]. Tertiary structure
prediction was carried out using I-TASSER tool [20].
Critical Assessment of Techniques for Protein Structure
Prediction (CASP) is a community-wide experiment for
testing the state-of-the-art of protein structure predictions
which takes place every two years since 1994. The I-
TASSER server (as “Zhang-Server”) participated in the
Server Section of 7th (2006), 8th (2008), and 9th CASPs
(2010), and was ranked as the No 1 server in CASP7,
CASP8 and CASP9. Thus, this server selected for tertiary
structure prediction. The c-score is a confidence score for
estimating the quality of predicted models by I-TASSER.
It is calculated based on the significance of threading tem-
plate alignments and the convergence parameters of the
structure assembly simulations. The c-score is typically in
the range of (−5, 2), where a c-score of higher value signi-
fies a model with a high confidence and vice-versa [20].
The quality of the predicted structure was examined using
an online metaserver SAVES, which uses Procheck [21],
WhatCheck [22], Verify3D [23], ERRAT [24] and PROVE
[25] servers. The predicted structure was refined using
SUMMA server [26]. Molecular dynamic analysis was car-
ried out using GROMACS (GROningen MAchine for
Chemical Simulations) software [27,28]. Structure
visualization was carried out using Accelrys’ Discovery
Studio Visualizer 1.7. Tertiary structure of osteopontin-a
also predicted by I-TASSER server and subjected to other
treatments as mentioned for osteopontin-c.Determination of conserved regions (domains)
In order to determine conserved regions (domains) in
osteopontin-c of human, it was aligned with rabbit, cattle,
chicken, house mouse, Norway rat and water buffalo osteo-
pontin sequences using clustalW [29] at http://www.gen-
ome.jp/tools/clustalw/. RSK and RGD domain comparison
was achieved by using Discovery Studio Visualizer (Accelrys
Discovery Studio Visualizer, version 1.7, 2007; Accelrys
Software Inc., San Diego). Tertiary structures of thrombin
cleaved fragments were also predicted by I-TASSER server.
The C-terminal fragment of osteopontin-c was used for
hypothetical polymer formation using ICM Molsoft tool.
Six subunits were utilized for the formation of polymer
formation using import option of the ICM Molsoft tool.
Docking
The predicted tertiary structures of osteopontin-a and
osteopontin-c were docked with CD44 using Cluspro.
ClusPro is the first fully integrated server that includes
both docking and discrimination steps for predicting the
structure of protein–protein complexes. The server can
be used to discriminate a set of potential complex struc-
tures from several docking algorithms, or it can generate
its own structures using DOT or ZDOCK [30].
Binding pockets predictions
PocketFinder and Q-Site finder were utilized for binding
pocket predictions [31]. PocketFinder is based on the
Ligsite algorithm written by Hendlich et al. [32] which
was used to predict small molecule binding sites in pro-
teins. Q-Site finder uses the interaction energy between
the protein and a simple van der Waals probe to locate
energetically favourable binding sites.
Druggable pocket predictions
DoGSiteScorer is an automated pocket detection and ana-
lysis tool which can be used for protein druggability as-
sessment. Based on the three dimensional coordinates of a
protein, its potential active sites on the protein surface are
calculated with DoGSiteScorer. DoGSiteScorer is a grid-
based function prediction method which uses a difference
of Gaussian filter to detect potential pockets on the pro-
tein surface and splits them into subpockets. Subse-
quently, global properties, describing the size, shape and
chemical features of the predicted pockets are calculated.
Per default, a simple score is provided for each pocket,
based on a linear combination on the three descriptors
describing volume, hydrophobicity and enclosure. For the
discrimination of the druggability, a subset of meaningful
descriptors is used in a support vector maschine (libsvm).
The druggability model was trained and tested on the
druggable cavity directory dataset consisting of 1069
structures and yielded prediction accuracies of 88%. For
each queried input structure, a druggability score
Table 2 I-TASSER scores for predicted models of
osteopontin-c
S. No Model C-Scores No. of decoys Cluster density
1. Model 1 −3.99 703 0.0237
2. Model 2 −3.56 544 0.0364
3. Model 3 −3.99 209 0.0237
4. Model 4 −4.61 199 0.0127
5. Model 5 −4.43 179 0.0151
Figure 1 Predicted structure of osteopontin-c by I-TASSER. Figure shows five predicted models from I-TASSER Server. Of these five models,
model 2 is reported as best model by comparing with the electron microscopic structure of Bone sialoprotein.
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the more druggable the pocket is estimated to be [33-35].
Results and discussion
Sequence analysis
Osteopontin-c gene sequence was determined from breast
cancer sample and deposited to Genbank with ID
JF412667. With the ExPASy Translate tool, a peptide
sequence was deduced, consisting of 287 amino acid resi-
dues. This sequence was 100% identical to the protein
sequence in GenPept database (NP_001035149.1). Both
the signal prediction tools namely SignalP and PrediSi in-
dicated the presence of a potential signal peptide in
osteopontin-c protein. Signal sequence prediction servers
predicted an N-terminal cleavage site between 16th and
17th amino acid residues of osteopontin-c sequence. After
predicting the signal sequence, first 16 amino acidresidues were identified as signal peptide and were re-
moved from osteopontin-c sequence. The remaining pro-
tein sequence was utilized for tertiary structure prediction
because during protein folding under in-vivo condition,
the signal sequence is removed.
X-ray crystallography, NMR and cryo-electron micro-
scopic studies were used in wet-lab for three dimensional
Figure 2 Superposition comparison for predicted and refined
structure of osteopontin-c. Here all conformations are
superimposed with a reference structure (Predicted model) using
RMSD fit. Accelry’s Discovery Studio Visualizer 1.7 was utilized for the
superimposition. A. predicted structure. B. Refined structure.
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ried out to predict three dimensional structure of only
RGD tripeptide sequence of osteopontin [37]. Prediction
of protein structure from amino-acid sequences has been
one of the most challenging problems in computational
structural biology for many years. Historically, protein
structure prediction was classified into three categories:
(i) comparative modeling, (ii) threading, and (iii) ab-initio
folding. The first two approaches build protein models by
aligning query sequences onto solved template structures.
When close templates are identified, high-resolution
models could be built by the template-based methods. If
templates are absent from the Protein Data Bank (PDB)Table 3 Significant SAVES validation server results of osteopo
S. No Servers Parameters
1. PROCHECK* G-Factor Value
2. WhatCheck* Bond Lengths
3. Verify3D* 3D – 1D score > 0.2
4. ERRAT# Overall Qualaity
5. PROVE* % Outliers
“*” - Lesser value indicates better quality.
“#” - Higher value indicates better quality.library, the models need to be built from scratch, i.e. ab-
initio folding. This is the most difficult category of protein
structure prediction. Such difficult task was attained using
I-TASSER tool [20]. Tertiary structure of osteopontin-c
was predicted using I-TASSER Server [38]. Predicted
tertiary structure is shown in Figure 1. I-TASSER result
provided five models with different c-scores, cluster dens-
ity and number of decoys as shown in Table 2.
Predicted model-2 contains the highest c-score and
also showed high similarity with electron microscopic
structure of bone sialoprotein (BSP), which belongs to
same Small integrin-binding ligand N-linked glycopro-
teins (SIBLINGs) protein family. Both the Predicted
model-2 and bone sialoprotein were found to have
thread with globular domain structure. Electron crystal-
lography is a form of microscopy that uses a beam of
electrons to construct images of small solids such as
proteins. This process is used to determine and predict
the structure and arrangement of a protein from second-
ary structure crystals such as alpha helices or beta sheets
based on electron scattering. By electron crystallography
method BSP structure determined. The BSP is a mono-
mer possessing a globular structure with a diameter of
10 ± 1 nm that is linked to a thread-like structure of
25 ± 6 nm length. The globule is likely to correspond
to the C-terminal part and the threadlike structure to
N-terminal part of the protein [39].
Small integrin-binding ligand N-linked glycoproteins
(SIBLINGs), a family of five integrin binding glycopho-
sphoproteins comprising osteopontin (OPN), bone sialo-
protein (BSP), dentin matrix protein 1 (DMP1), dentin
sialophosphoprotein (DSPP) and matrix extracellular
phosphoglycoprotein (MEPE), are an emerging group of
molecular tools that cancer cells use to facilitate their
expansion. SIBLINGs are soluble, secreted proteins that
can act as modulators of cell adhesion as well as auto-
crine and paracrine factors by their interaction with cell
surface receptors such as integrins. BSP and OPN are
two members of the SIBLING family of genetically
related proteins that are clustered on human chromosome
4. These two proteins have several common binding
partners like CD44, integrins, matrix metalloproteinasesntin-c
Before refinement After refinement





Figure 3 The Root mean square deviation plot (Carbon Alpha
back bone) obtained from GROMACS tool during molecular
dynamics simulation for 10 nanoseconds. Root mean square
deviation (RMSD) of osteopontin-c model during the molecular
dynamics (MD) simulation. The stabilization of the structure occurred
in approximately 10 ns. Generated by GROMACS.
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they had common interaction domains like RGD and in
turn structure [40,41].
Predicted tertiary structure of osteopontin-c had
three domains, namely N-terminal domain, central do-
main and C-terminal domain. RGD and RSK motifs
and two helical regions and three turns were present in
central domain. N-terminal end domain consists of
four antiparallel sheets, two helical regions and five turns.
C-terminal end domain consists of one sheet, one helical
region and one turn. Earlier hypothetical structure for
osteopontin was predicted by Ganss. It was an open
extended and flexible structure. Model-2 of I-TASSER
result supported the proposal of Ganss [42].
Model-2 was refined using SUMMA Server. The pre-
dicted structure was refined by fixing side chains, fixing
problematic loops, removal of amino acid clashes
(bumps) and energy minimization. Potential functions
used in structure prediction and refinements are typic-
ally grouped into two general classes: traditional “phys-
ical” molecular mechanics potentials and statistically
derived ‘knowledge-based” potentials [26]. The refine-
ments did not yield any drastic change in the initial pre-
dicted structure augmenting the correctness of the
predicted structure, which was confirmed by superim-
position studies.Figure 4 Selected structural domains and their corresponding locatioRefined structure and predicted structure were super-
imposed using Accelry’s Discovery Studio Visualizer 1.7
software. RMSD value for the superimposition was
found to be 0.92 A°. The superimposed structure is
shown in Figure 2. It was found that the structure of
osteopontin-c was similar in structure to fibronectin
which was determined by Amit sharma et al., [43]. Fi-
bronectin (FN) is a large glycoprotein found on cell sur-
faces, in the connective tissue matrix and in extracellular
fluids. It participates in cell adhesion, spreading, migra-
tion, extracellular matrix formation, hemostasis and
thrombosis. FN binds to fibrin, collagens, gelatin, DNA,
integrins, heparin and proteoglycans. Due to the com-
mon interacting partners both have similar structures
[43].
SAVES validation server results showed that refined
structure was slightly improved from the predicted
structures. Comparisons of validation server results are
listed in the Table 3. Lesser values in ProCheck,
WhatCheck and PROVE servers result of refined struc-
ture showed that the structure quality was improved.
Verify 3D values were found to be insignificant. Higher
value in ERRAT result also supported the structure re-
finement process. Molecular dynamics (MD) is a com-
puter simulation of physical movements of atoms and
molecules [44]. Molecular dynamic simulation with ex-
plicit waters for 10 nanoseconds was assessed by GRO-
MACS software [45]. The root-mean-square deviation
(RMSD) variations for the molecular dynamic simulation
are given in the Figure 3. It clearly showed that
osteopontin-c had average RMSD deviation of 2.79 A°.
Anyway, the refined structure was found to be an im-
proved one. But one cannot reject predicted structure of
osteopontin-c because the structure does not showed
drastic variation in tertiary structure during molecular
dynamic simulations. RMSD values below 5–6 A° are
generally considered being characteristic for a stable
protein in molecular dynamics simulations [46].
Determination of conserved regions (domains)
The amino acid sequences of osteopontin were derived
from human [47], mouse [48], rat [49], rabbit [50], Water
buffalo [51] and cattle [52]. Multiple sequence alignment
was carried out using ClustalW program at Eurobean
Bioinformatic Institute. Based on sequence alignments, the
amino acid sequence was divided into nine parts which
were represented in Figure 4. Of these nine parts, only fivens in the human osteopontin-c.
Sivakumar and Niranjali Devaraj Journal of Diabetes & Metabolic Disorders 2014, 13:13 Page 7 of 14
http://www.jdmdonline.com/content/13/1/13parts have known functions i.e. PolyD – Binds with calcium,
RGD – Integrin binding site, GLRS – Thrombin cleavage
site, Eighth part – Calcium Binding site, and Ninth part-
Heparin Binding site. Of these conserved regions, Poly D
(4th), GRGDS (6th) and GLRS (7th) regions are well known
for their functions [53]. Human and Rabbit sequences were
found to have 64% similarity whereas human and chickenFigure 5 Multiple sequence alignment of osteopontin. Multiple sequen
Bubalus bubalis (water buffalo), Homo sapiens (human), Oryctolagus cuniculu
Gallus gallus (chicken). The *(star) in the sequence represents identical residwere found to have only 21% similarity score in multiple se-
quence alignment. Multiple sequence alignment is shown in
Figure 5. Phylogenetic relationships between these organisms
are shown in Figure 6. Distinct differences were found to be
present between human and chicken which could reflect
functional and developmental differences between chicken
and mammalian osteopontins [54].ce alignment of osteopontin amino acid residues of Bos taurus (cattle),
s (rabbit), Mus musculus (mouse), Rattus norvegicus (Norway rat) and
ues.
Figure 7 RGD and RSK domains of osteopontin-c and osteopontin-a.
remaining part of the protein is represented in solid ribbon model using A
Figure 6 Phylogenetic tree. Phylogenetic tree obtained using a
multiple alignment of osteopontin protein sequences from cattle
(NP_776612), water buffalo (ABD73011), human (NP_001035149.1),
rabbit (NP_001075663), mouse (NP_033289), rat (NP_037013) and
chicken (NP_989866). See text for details.
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RGD and RSK motifs which can be seen in Figure 7. Dif-
ference in the role of osteopontin-c from osteopontin-a in
cancer can be clearly seen from Figure 7 that is the expos-
ure of RSK domain. Due to the exposure of RSK domain,
thrombin can easily cleave osteopontin-c into two frag-
ments N-terminal and C-terminal fragments. The frag-
ments were then subjected to tertiary structure prediction.
Predicted structures of N-terminal and C-terminal frag-
ments are shown in Figure 8. Predicted structure showed
totally different structure when compared with the intact
osteopontin-a and osteopontin-c. This might be the essen-
tial reason for the role of osteopontin-c in cancer progres-
sion and metastasis. C-terminal fragments’ polymer might
form channel like structures which is shown in Figure 8.
Presence of RGD and RSK motifs in osteopontin were re-
ported by several studies [55,56]. Thrombin cleaves be-
tween R and S residues of RSK sequence [55,56]. This
cleavage occurs within six amino acid residues of the
GRGDS sequence, raising the interesting possibility that
thrombin-cleavage further activates osteopontin by allow-
ing greater accessibility of the GRGDS domain to cell sur-
face receptors [57-60]. Xuan et al. [61] have shown that
thrombin cleavage of osteopontin abolishes its cell binding
function. The N-terminal GRGDS-containing osteopontin
thrombin-cleavage fragment is highly active in promoting
tumor cell migration [62]. The N-terminal fragment
contains two integrin binding sites. These integrin
binding domains include a SVVYGLR domain and a
well-characterized RGD domain [63,64]. Furthermore,
a recent study by Mi et al. [65] demonstrated that theRGD and RSK domains are represented in ball and stick model whereas
ccelry’s Discovery Studio Visualizer 1.7.
Figure 8 N-terminal fragment (A) and C-terminal fragment (B) of osteopontin-c after the action of thrombin. Polyimerized structure
(C) of C-terminal fragment of osteopontin-c. RGD domains are represented in ball and stick model in N-terminal fragment. Alternate presence of
helices might be seen in C-terminal fragment which might provide the clue for the formation of pore or fibre. Tube and surface model are
represented in the Figure C. Polymerization was achieved using ICM Molsoft Tool.
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pontin can activate downstream signaling and influence
breast cancer cell migration and invasion in-vitro. The
COOH-terminal fragment of osteopontin binds with
another marker of metastatic function (cyclophilin C or
rotamase) to the CD147 cell surface glycoprotein (also
known as extracellular matrix metalloproteinase in-
ducer or EMMPRIN), to activate Akt1/2 and matrix
metalloproteinase-2 [65,66].
Previous studies in bovine osteopontin clearly dem-
onstrated that gln-x-gln sequence is required for trans-
glutaminase activity of cross linking osteopontin
through gamma-glutamyl-epsilon-lysino peptidyl bond
formation [67]. Multiple sequence alignment in
Figure 9 clearly showed that the transglutaminase act-
ing site is not present in osteopontin-c. The probable
site is present between 46th and 52nd residues
(PDPSQKQ) in osteopontin-a. The absence of this
region in osteopontin-c clearly showed that transgluta-
minase will not act on it. This might be the essential
reason for the pathological role of osteopontin-c andit may not be crosslinked with extracellular matrix
and thus it results in cell migration. This fact was
also supported by the lack of exon-4 expression in
osteopontin-c by Weber [15].
Docking
Interestingly, OPN binding to CD44 results in the
propagation of cytosolic signals that enhance integrin ac-
tivation and thus migration in cancer cells. Binding of
OPN with CD44 actively promote local proteolysis
through binding with MMP3 and also activate comple-
ment factor H (CF-H) which protects cancer cell from
complement mediated lysis. Both integrins and CD44
have well-established roles in tumor progression. There-
fore, interfering with these receptor–ligand interactions
by controlling receptor cell surface expression, blocking
receptor–ligand binding or suppressing associated signal
transduction are promising ways to block both tumor
development and metastatic dissemination [40]. Thus,
CD44 is selected as a potential receptor for docking
studies. Docking analysis was carried out using CD44 as
Figure 9 Multiple sequence alignment comparison between osteopontin-a and osteopontin-c with other species with respect to
transglutaminase acting stie. Alignment analysis clearly showed the absence of transglutaminase site in osteopontin-c. Transglutaminase-2
acting site is indicated by an open box.
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osteopontin-c as ligands. Docking results were analyzed
manually and interaction sites were analyzed using Dis-
covery Studio Visualizer 1.7 neighbour analysis tool. The
results of ClusPro docking studies between CD44 and
osteopontin-a and osteopontin-c showed for the first
time that both of them interact in a similar site. Inter-
action of osteopontin to CD44 was proved by many
studies [39,68] but none of the previous studies deter-
mined the interaction sites. Docked structures of CD44
and osteopontins and the interaction domains of CD44
and osteopontins were shown in Figure 10. It was identi-
fied that aspargine (233rd residue), serine (234th resi-
due) and threonine (237th residue) residues were
essential for interactions in osteopontin isoform se-
quences. These residues might form the QSAET motif
essential for the interaction of CD44 and osteopontins
which is reported first time in the present study. Of
these three residues, serine and threonine were found to
be highly conserved in various species as was evident
from the multiple sequence alingment. As the outcome,it was found out that serine and threonine residues are
essential for interaction with CD44. This result supports
the result of serine (234th residue) residue being glyco-
sylated as a post translational modification in human
osteopontin [69].
Binding pockets prediction
Binding pockets prediction is an essential step towards
drug designing and docking studies [70]. Predicted binding
pockets are shown in Figure 11. Pocket Finder detected ten
pockets in both osteopontin-a and osteopontin-c. Eighth
pocket of osteopontin-a was found to be present in the
close region of RSK motif whereas no pocket contains
RGD motif. First pocket of osteopontin-c was found to
contain both RSK and RGD motifs. This result again con-
firms the role of osteopontin-c in cancer biology with
respect to RSK and RGD motifs. Q-site finder predicted
ten binding pockets from both osteopontin-a and
osteopontin-c. Osteopontin-a has two pockets, namely,
sixth and seventh, which contain RSK and RGD motifs in
its outer layer, respecively. Osteopontin-c was found to
Figure 10 Docked structure of CD44 with osteopontin-c and osteopontin-a. A. Docked structure of CD44 (red) and osteopontin-a (green)
and osteopontin-c (purple). B. Interaction site of CD44 (red) and osteopontin-a (blue). C. Interacation site of CD44 (red) and osteopontin-c (blue).
It was achieved using Accelry’s Discovery Studio Visualizer 1.7 Tool.
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tifs, respectively. From all these results, the main novelty
identified was that osteopontin-c contains binding pockets
with highest rank with RGD and RSK motif, whereas
osteopontin-a does not. Osteopontin promotes tumor
growth and metastasis through the RGD domain [9].
Druggable pocket identification
Pockets are ranked according to interaction energy, and
it is assumed that these relate to locations where a puta-
tive ligand could bind and optimise its van der Waals
interaction energy. The total energy of the pocket de-
fines its ability to bind a small molecule and therefore
its druggability [71]. Druggable pockets differ from bind-
ing pockets because druggable pocket was predicted
using the druggable cavity directory dataset of drugs. A
druggable pocket in osteopontin-c was predicted by
DoGSiteScorer [34] and manual inspection of the pocket
with their energies with the help of Swiss PDB Viewer
3.7 tool. It was found that the Q-site finder predicted
eighth pocket with APSD (170th to 173rd residues) andTSQLD (184th to 188th residues) motifs can be used as
a drug target in osteopontin-c due to the presence of
pocket with maximum energy and druggable score. Amino
acid residues of this predicted pocket was found to be con-
served which was proved by multiple sequence analysis
[Figure 5]. Elevated expression of osteopontin-c has been
found in many cancers and the level of its expression is
associated with the metastatic potential of cancer. Thus
targeting osteopontin using the druggable pocket would be
a logical approach for cancer management [72].
Conclusion
The key finding of the present study is the discovery, for
the first time, of the binding site of CD44 in osteopontin-c
which has aspargine (233rd residue), serine (234th
residue) and threonine (237th residue) residues. During
the course of the study, a novel druggable pocket with
APSD and TSQLD motifs was also found, which will be
useful for future computer aided drug designing studies.
Another important finding is that the RSK sequence is
exposed to thrombin in osteopontin-c splice variant only
Figure 11 Predicted binding pockets in osteopontin-c and osteopontin-a. PocketFinder and Q-site Finder predicted pockets in osteopontin-a
and osteopontin-c are shown as groups.
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plains the fact that only osteopontin-c is involved in me-
tastasis. Due to the action of thrombin, osteopontin-c is
fragmented into N-terminal and C-terminal fragments
easily. Hypothetical proposal for the formation of channel
like conformation by osteopontin-c was achieved with
help of C-terminal fragment and favors cancer cell migra-
tion and metastasis. Absence of “PDPSQKQ” sequence in
osteopontin-c avoids full length protein polymerization by
transglutaminase-2 and favors metastasis. On the other
hand, full length osteopontin-a is polymerized by
transglutaminase-2 and thus, osteopontin-a cannot help
metastasis because polymer favors cell adhesion. Obvi-
ously, experimental elucidation might be useful for furthervalidation of real time tertiary structure of osteopontin-c.
Until then, the present predicted structure might be
used for computational drug design for osteopontin-c
with respect to prevention of cancer.Competing interests
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